Knives out at ODAC with vote against accelerated approval for Spectrum lung cancer drug
Following the release of scathing briefing documents earlier this week, FDA reviewers continued to lambast Spectrum Pharmaceuticals’ potential lung cancer drug poziotinib, and outside advisors …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
